Acetazolamide has been used in CACNA1A patients to prevent FHM (26), and a recently designed non-commercial clinical trial using acetazolamide in PMM2-CDG to improve cerebellar syndrome also showed improvement in a treated patient who suffered from almost weekly SLE episodes together with migraine. This evidence concerns the gene CACNA1A and migraine disorder.